Inositec AG

Swiss Biotech Association

Member

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

LATAM Pharma Innovative Ventures AG

LATAM Pharma offers made-to-measure solutions of immunization to public and private markets in Latin American and Caribbean countries.
6300 Zug

Member

Onward Therapeutics SA

We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.
1066 Épalinges

Member

NovaGo Therapeutics

NovaGo is focused on human antibody therapeutics targeting blood vessel & nerve growth. Our proprietary antibodies target Nogo-A, one of the most potent vascular & nerve growth inhibitors & have the potential to be a safe & effective treatment in ophthalmology and central nervous system indications.
8952 Schlieren

Member